

# Illness Severity in Hospitalized Influenza Patients by Virus Type and Subtype, Spain, 2010–2017

Concepción Delgado-Sanz, Clara Mazagatos-Ateca, Jesús Oliva, Alin Gherasim, Amparo Larrauri

## Medscape **ACTIVITY** EDUCATION

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 **AMA PRA Category 1 Credit(s)**<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at <http://www.medscape.org/journal/eid>; and (4) view/print certificate. For CME questions, see page 400.

**Release date: January 16, 2020; Expiration date: January 16, 2021**

### Learning Objectives

Upon completion of this activity, participants will be able to:

- Compare clinical characteristics and epidemiology among SHCIC caused by different virus types and subtypes in Spain from 2010 to 2017, according to a retrospective cohort study
- Compare outcomes among SHCIC caused by different virus types and subtypes in Spain from 2010 to 2017, according to a retrospective cohort study
- Describe clinical implications of findings regarding SHCIC caused by different virus types and subtypes in Spain from 2010 to 2017, according to a retrospective cohort study

### CME Editor

**Jude Rutledge, BA**, Technical Writer/Editor, Emerging Infectious Diseases. *Disclosure: Jude Rutledge has disclosed no relevant financial relationships.*

### CME Author

**Laurie Barclay, MD**, freelance writer and reviewer, Medscape, LLC. *Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.*

### Authors

*Disclosures: Concepción Delgado-Sanz, MD, MPH; Clara Mazagatos-Ateca, MSc; Jesús Oliva Dominguez, MD, PhD; Alin Manuel Gherasim, MD; and Amparo Larrauri, MPharm, PhD, have disclosed no relevant financial relationships.*

Author affiliations: European Centre for Disease Prevention and Control, Stockholm, Sweden (C. Delgado-Sanz); Institute of Health Carlos III, Madrid, Spain (C. Delgado-Sanz, C. Mazagatos-Ateca, J. Oliva, A. Gherasim, A. Larrauri); CIBER Epidemiología y

Salud Pública, Madrid (C. Delgado-Sanz, C. Mazagatos-Ateca, J. Oliva, A. Gherasim, A. Larrauri)

DOI: <https://doi.org/10.3201/eid2602.181732>

We conducted a retrospective cohort study to assess the effect of influenza virus type and subtype on disease severity among hospitalized influenza patients in Spain. We analyzed the cases of 8,985 laboratory-confirmed case-patients hospitalized for severe influenza by using data from a national surveillance system for the period 2010–2017. Hospitalized patients with influenza A(H1N1)pdm09 virus were significantly younger, more frequently had class III obesity, and had a higher risk for pneumonia or acute respiratory distress syndrome than patients infected with influenza A(H3N2) or B ( $p < 0.05$ ). Hospitalized patients with influenza A(H1N1)pdm09 also had a higher risk for intensive care unit admission, death, or both than patients with influenza A(H3N2) or B, independent of other factors. Determining the patterns of influenza-associated severity and how they might differ by virus type and subtype can help guide planning and implementation of adequate control and preventive measures during influenza epidemics.

**D**uring the 2009 influenza pandemic, influenza surveillance activities were intensified in Spain (1). In accordance with international recommendations (2), Spain established surveillance of Severe Hospitalized Confirmed Influenza Case-patients (SHCIC) to monitor the evolution of severe influenza during pandemics and inter-pandemic influenza.

In the years since the 2009 influenza pandemic, SHCIC surveillance has become a consolidated severe influenza surveillance system that operates within the Spanish Influenza Surveillance System (3; Appendix, <https://wwwnc.cdc.gov/EID/article/26/2/18-1732-App1.pdf>). The system provides a standardized tool to monitor risk factors associated with severe influenza, identify influenza viruses associated with severe clinical manifestations, and monitor the disease burden of influenza epidemics. Sentinel hospitals belonging to the public health system of all 19 regions of Spain are involved in SHCIC surveillance (3).

The association of certain influenza virus types and subtypes with disease severity has been a major topic of influenza research in recent years (4–10). However, after the 2009 pandemic, findings on the severity of epidemics by type and subtype of influenza virus have varied widely. Some studies have reported no statistically significant differences in case-fatality rates and other markers of severity by type and subtype of influenza infections (4) and have shown that the risk for serious outcomes was not increased in hospitalized influenza patients infected with influenza A(H1N1)pdm09 (pH1N1) compared with seasonal influenza B viruses (5,6). In contrast, other authors have indicated that, in hospitalized influenza patients, pH1N1

infection is more clinically severe than influenza A(H3N2) or B infection (7–10).

SHCIC surveillance provides a reliable platform to monitor different influenza viruses associated with severe disease. By using the framework of this surveillance system, we aimed to explore disease severity of hospitalized influenza patients in Spain according to influenza virus type and subtype during the 7 influenza seasons that followed the 2009 pandemic.

## Material and Methods

We conducted a retrospective cohort study by using SHCIC surveillance data obtained across the 7 postpandemic influenza seasons (2010–11 through 2016–17). The SHCIC surveillance system is a passive, hospital-based surveillance system that includes 90–181 reporting hospitals during the study period; these hospitals are located throughout Spain and serve 45%–60% of the population of Spain, depending on the influenza season.

Each influenza season was defined as lasting from week 40 of the first year to week 20 of the following year. As part of the surveillance, clinicians in the participating hospitals were advised to swab any person with clinical suspicion of influenza-like illness (without specific case definition) and who required hospital admission to any hospital ward. A severe hospitalized confirmed influenza case-patient was defined as any person with a clinical profile compatible with influenza-like illness who had laboratory confirmation of influenza infection (Appendix) and who was hospitalized according to  $\geq 1$  of the following clinical criteria: pneumonia, acute respiratory distress syndrome (ARDS), multiple organ dysfunction syndrome (MODS), septic shock, or admission to an intensive care unit (ICU). The case-patient definition was unchanged throughout the study period.

Variables collected for surveillance purposes included demographic characteristics (age and sex), dates of symptom onset and hospitalization, virus type and subtype, presence of underlying medical conditions (any chronic respiratory, cardiovascular, renal or liver disease, class III obesity, diabetes mellitus, or immunosuppression), complications (pneumonia, any laboratory-confirmed viral or bacterial coinfection, ARDS, or MODS), antiviral treatment, time from symptom onset to start of antiviral treatment, influenza vaccination status, date of vaccination, admission to ICU, outcome (alive or dead), region, and influenza season. Class III obesity was defined as a body mass index  $\geq 40$  kg/m<sup>2</sup>. We obtained vaccination status by using clinical history and vaccination registries. We considered a patient to be correctly

vaccinated if she or he received the vaccine  $\geq 15$  days before symptom onset.

We calculated the percentage of patients with a specific condition by using the number of patients with available information regarding the condition. Our analysis excluded patients whose influenza A subtype was unknown. We calculated the percentage of pregnant women by using all women of childbearing age (15–49 years of age) as the denominator.

We used univariate multinomial logistic regression models to compare demographic and clinical characteristics across virus types and subtypes, including as a dependent variable the influenza virus type and subtype, with pH1N1 used as reference, and as independent variables each of the characteristics of interest. We measured the effect of each predictor in the model as a relative risk ratio (RRR). We also conducted univariate logistic regression models to estimate the odds ratios (ORs) and 95% confidence intervals for the risk for clinical complications or death, considering influenza virus type and subtype to be an explanatory variable and using influenza pH1N1 as reference. We compared patients infected with influenza A(H3N2) or B against patients infected with pH1N1.

In addition, we applied multivariable logistic regression models, stratified by age group, to explore the effect of influenza virus type and subtype as an independent factor for the following severe outcomes: ICU admission, death, or both, using pH1N1 as reference. We adjusted all of these models for potential confounding such as sex, age, influenza season, underlying medical conditions, pneumonia, antiviral treatment, and receipt of seasonal trivalent influenza vaccine.

For all statistical analyses, we considered 2-sided *p* values  $< 0.05$  to be statistically significant.

We performed the analyses by using Stata 14.0 (<https://www.stata.com>)


This study was conducted within the framework of ongoing SHCIC surveillance by the Institute of Health Carlos III, National Epidemiology Centre. A formal ethics review was not required because the study was part of the routine surveillance activities in Spain. However, we collected anonymized data and obtained verbal consent from all patients before they were swabbed for surveillance purposes.

## Results

During September 2010–May 2017, a total of 12,942 case-patients were reported in Spain. We included 8,985 patients with complete influenza virus type and subtype information in our study; 4,568 (51%) were infected with pH1N1, 3,091 (34%) with influenza A(H3N2), and 1,326 (15%) with influenza B.

SHCIC surveillance indicated week-by-week patterns that matched the epidemiologic patterns for influenza in the community based on the sentinel system for primary care. The identified influenza virus types and subtypes among case-patients were consistent with the type and subtype of influenza virus circulating within the general population (Figure 1). pH1N1 was the dominant subtype among case-patients during the 2010–11, 2013–14, and 2015–16 seasons; influenza A(H3N2) during the 2011–12, 2014–15, and 2016–17 seasons; and influenza B during the 2012–13 season. Also, we noted a substantial contribution from influenza B infections during the influenza A(H3N2)-dominant 2014–15 season and after the peak of the pH1N1-dominant 2015–16 influenza season (Figure 1).

The distribution of case-patients by age group varied according to the circulating virus type and




**Figure 1.** Number of patients hospitalized for laboratory-confirmed severe influenza, by influenza virus type or subtype and week of hospital admission, Spain, influenza seasons 2010–11 to 2016–17. Seasonal epidemic periods are labeled with dominant circulating virus.

subtype in each influenza season (Figure 2). In seasons with dominant pH1N1 circulation (Figure 2, panels A, C, and F), most patients (52%) were persons 15–64 years of age. Patients  $\geq 65$  years of age accounted for 65% of case-patients in those seasons with dominant influenza A(H3N2) circulation (Figure 2, panels B, E, and G); however, during the 2011–12 season, a relatively high percentage (33%) of case-patients were children. In the 2012–13 season, 54% of case-patients 15–64 years of age were infected with pH1N1, whereas 89% of case-patients 5–14 years of age were infected with influenza B (Figure 2, panel C). In general, case-patients infected with pH1N1 were significantly younger (median age 53 years [interquartile range (IQR) 37–66 years]) than those infected with influenza A(H3N2) (median age 73 years [IQR 56–83 years]) and influenza B (median age 60 years [22–74 years]) ( $p < 0.001$ ).

Regarding the clinical characteristics, case-patients infected with influenza A(H3N2) or B virus were more likely to have  $\geq 1$  underlying medical conditions compared with those with pH1N1 infection (crude RRR [cRRR] 2.81 [95% CI 2.45–3.22] for influenza A[H3N2]-infected patients and cRRR 1.32 [95% CI 1.13–1.55] for influenza B-infected patients) (Table 1). This pattern also was observed for chronic respiratory, cardiovascular, and renal diseases. However, immunosuppression was less likely among influenza A(H3N2)-infected patients than pH1N1-infected patients (cRRR 0.72 [95% CI 0.63–0.84]). Class III obesity was less frequent among influenza A(H3N2)-infected patients (cRRR 0.66 [95% CI 0.55–0.78]) and influenza B-infected patients (cRRR 0.59 [95% CI 0.46–0.75]) than among pH1N1-infected patients. Among women 15–49 years of age, fewer pregnancies were observed among influenza A(H3N2)-infected patients

than pH1N1-infected patients (cRRR 0.33 [95% CI 0.17–0.64]). Patients infected with influenza A(H3N2) or B virus were less likely to receive antiviral treatment than those infected with pH1N1 (cRRR 0.48 [95% CI 0.42–0.54] for influenza A[H3N2]-infected patients and cRRR 0.30 [95% CI 0.26–0.34] for influenza B-virus infected patients) (Table 1). The median days from symptom onset to hospitalization was longer among pH1N1-infected patients (4 days [IQR 2–6 days]) than for influenza A(H3N2)-infected patients (3 days [IQR 1–5 days]) ( $p < 0.001$ ).

The analysis of clinical complications and outcome revealed that patients with influenza A(H3N2) and B virus infection had lower risk for pneumonia (crude OR [cOR] 0.68 [95% CI 0.61–0.76] for influenza A[H3N2]-infected patients and cOR 0.77 [95% CI 0.67–0.89] for influenza B-virus infected patients), ARDS (cOR 0.69 [95% CI 0.61–0.77] for influenza A[H3N2]-infected patients and cOR 0.73 [95% CI 0.63–0.85] for influenza B-virus infected patients), and ICU admission (cOR 0.55 [95% CI 0.50–0.61] for influenza A[H3N2]-infected patients and cOR 0.64 [95% CI 0.56–0.73] for influenza B-virus infected patients) compared with patients with pH1N1 infection (Table 2). However, patients infected with influenza A(H3N2) or B had a higher risk for co-infection (cOR 1.23 [95% CI 1.09–1.38] for influenza A[H3N2]-infected patients and cOR 1.43 [95% CI 1.22–1.67] for influenza B-virus infected patients). The case-fatality rate was significantly higher among influenza A(H3N2)-infected patients (cOR 1.25 [95% CI 1.10–1.43]) than for pH1N1-infected patients. The risk for death was significantly lower for those patients infected with influenza B (cOR 0.76 [95% CI 0.62–0.93] for patients hospitalized and cOR 0.73 [95% CI 0.55–0.97] for those admitted to ICU) than patients with pH1N1 infection.



**Figure 2.** Number of patients hospitalized for laboratory-confirmed severe influenza, by influenza virus type or subtype and age group, Spain, influenza seasons 2010–11 to 2016–17. A) 2010–11 season. B) 2011–12 season. C) 2012–13 season. D) 2013–14 season. E) 2014–15 season. F) 2015–16 season. G) 2016–17 season.

**Table 1.** Demographic and clinical characteristics of patients hospitalized for laboratory-confirmed severe influenza, by influenza virus type or subtype, Spain, influenza seasons 2010–11 to 2016–17\*

Characteristic	Influenza virus type or subtype				
	pH1N1	A(H3N2)		B	
	No. (%)	No. (%)	Crude RRR† (95% CI)	No. (%)	Crude RRR‡ (95% CI)
Total no. patients	4,568 (100)	3,091 (100)	NA	1,326 (100)	NA
Age group, y					
<15	566 (12)	333 (11)	Referent	318 (24)	Referent
15–64	2,767 (61)	716 (23)	0.44 (0.38–0.52)	437 (33)	0.28 (0.24–0.33)
≥65	1,231 (27)	2,035 (66)	2.81 (2.41–3.27)	567 (43)	0.82 (0.69–0.97)
Missing data	4 (0.1)	7 (0.2)	NA	4 (0.3)	NA
Sex					
M	2,589 (57)	1,637 (53)	0.86 (0.78–0.94)	736 (56)	0.96 (0.85–1.08)
F	1,977 (43)	1,453 (47)	Referent	588 (44)	Referent
Missing data	2 (0.1)	1 (0.1)	NA	2 (0.2)	NA
Underlying medical condition§	2,334 (68)	2,055 (86)	2.81 (2.45–3.22)	754 (74)	1.32 (1.13–1.55)
Missing data	1,161 (25)	700 (23)	NA	310 (23)	NA
Class III obesity (BMI ≥40 kg/m <sup>2</sup> )	447 (12)	205 (8)	0.66 (0.55–0.78)	80 (7)	0.59 (0.46–0.75)
Chronic respiratory diseases	686 (22)	680 (30)	1.53 (1.35–1.73)	238 (25)	1.20 (1.01–1.42)
Chronic cardiovascular diseases	800 (21)	1,051 (40)	2.49 (2.23–2.78)	308 (28)	1.45 (1.24–1.69)
Diabetes mellitus	696 (18)	755 (29)	1.81 (1.61–2.04)	225 (20)	1.15 (0.97–1.36)
Renal diseases	335 (9)	394 (15)	1.87 (1.60–2.18)	132 (12)	1.42 (1.14–1.75)
Chronic liver disease	212 (6)	147 (6)	1.02 (0.82–1.26)	58 (5)	0.94 (0.70–1.27)
Immunosuppression	632 (17)	327 (13)	0.72 (0.63–0.84)	170 (16)	0.92 (0.77–1.11)
Pregnancy¶	125 (24)	11 (10)	0.33 (0.17–0.64)	18 (24)	0.98 (0.56–1.73)
Missing data	134 (20)	30 (21)	NA	19 (20)	NA
Antiviral treatment	3,787 (86)	2,241 (75)	0.48 (0.42–0.54)	800 (64)	0.30 (0.26–0.34)
Missing data	165 (4)	86 (3)	NA	86 (6)	NA
Oseltamivir	3,709 (99.3)	2,209 (99.7)	NA	777 (99.4)	NA
Zanamivir	16 (0.4)	3 (0.1)	NA	4 (0.5)	NA
Other	11 (0.3)	5 (0.2)	NA	1 (0.1)	NA
Seasonal trivalent influenza vaccine	514 (14)	862 (36)	3.45 (3.05–3.91)	261 (27)	2.18 (1.84–2.58)
Missing data	961 (21)	727 (24)	NA	345 (26)	NA

\*BMI, body mass index; RRR, relative risk ratio; NA, not applicable.

†Influenza A(H3N2) compared with pH1N1 (reference).

‡Influenza B compared with pH1N1 (reference).

§Underlying medical conditions defined as ≥1 of the following: class III obesity (BMI ≥40 kg/m<sup>2</sup>), chronic respiratory diseases, chronic cardiovascular diseases, diabetes mellitus, renal diseases, chronic liver disease, or immunosuppression.

¶Pregnancy among women of childbearing age (15–49 years).

We used a multivariable logistic regression analysis to explore the effect of influenza virus type and subtype on the severity of outcomes, such as ICU admission, death, or ICU admission and death, according to age group (Appendix Table 1). Case-patients >15 years of age who had influenza A(H3N2) or B infection showed less risk for death or ICU admission than patients infected with pH1N1, independent of other risk factors (Appendix Table 1). The pattern for all case-patient age groups combined was similar. When we compared pH1N1-infected patients with the other 2 patient groups, we observed significant differences in risk for ICU admission among influenza A(H3N2)-infected patients (adjusted OR [aOR] 0.56 [95% CI 0.44–0.71]) and influenza B-infected patients (aOR 0.51 [95% CI 0.41–0.63]); risk for death among influenza A(H3N2)-infected patients (aOR 0.56 [95% CI 0.40–0.77]) and influenza B-infected patients (aOR 0.38 [95% CI 0.26–0.54]); and risk for ICU admission and death among influenza A(H3N2)-infected patients (aOR 0.59 [95% CI 0.47–0.73]) and for

influenza B-infected patients (aOR 0.50 [95% CI 0.44–0.62]). However, among children <15 years of age, we observed no significant differences in the severity of outcome by virus type and subtype. In addition, we observed no difference in the risk for ICU admission between different influenza A subtypes among patients ≥65 years of age (Appendix Table 1).

## Discussion

Our findings show that SHCIC surveillance has provided valuable information on disease severity by influenza virus type and subtype since the 2009 pandemic. We found that case-patients infected with pH1N1 were significantly younger than those infected with influenza A(H3N2) or B and had a higher risk for clinical complications and severe outcomes, such as ICU admission, death, or both compared with case-patients with influenza A(H3N2) or B virus infections.

During the 2011–12 and 2012–13 seasons, an unexpectedly low number of case-patients were reported compared with previous seasons. Similar

**Table 2.** Clinical complications and final outcomes of patients hospitalized for laboratory-confirmed severe influenza, by influenza virus type or subtype, Spain, influenza seasons 2010–11 to 2016–17\*

Complication and outcome	Influenza virus type or subtype				
	pH1N1	A(H3N2)		B	
	No. (%)	No. (%)	Crude OR† (95% CI)	No. (%)	Crude OR‡ (95% CI)
Total no. patients	4,568 (100)	3,091 (100)	NA	1,326 (100)	NA
Pneumonia	3,529 (78)	2,154 (71)	0.68 (0.61–0.76)	951 (74)	0.77 (0.67–0.89)
Missing data	71 (2)	69 (2)	NA	36 (3)	NA
Co-infection	903 (26)	680 (31)	1.23 (1.09–1.38)	320 (34)	1.43 (1.22–1.67)
Missing data	1,153 (25)	873 (28)	NA	383 (29)	NA
ARDS	1,220 (29)	571 (22)	0.69 (0.61–0.77)	271 (23)	0.73 (0.63–0.85)
Missing data	405 (9)	528 (17)	NA	160 (12)	NA
MODS	405 (10)	236 (9)	0.94 (0.79–1.11)	107 (9)	0.94 (0.75–1.17)
Missing data	467 (10)	559 (18)	NA	177 (13)	NA
ICU admission	1,787 (41)	820 (28)	0.55 (0.50–0.61)	389 (31)	0.64 (0.56–0.73)
Missing data	245 (5)	146 (5)	NA	77 (6)	NA
Case-fatality rate					
Deaths in hospitalized patients	585 (14)	493 (16)	1.25 (1.10–1.43)	130 (11)	0.76 (0.62–0.93)
Deaths in ICU patients	405 (24)	180 (23)	0.90 (0.74–1.11)	68 (19)	0.73 (0.55–0.97)
Missing data	254 (6)	89 (3)	NA	109 (8)	NA

\*ARDS, acute respiratory distress syndrome; ICU, intensive care unit; MODS, multiple organ dysfunction syndrome; NA, not applicable; OR, odds ratio.

†OR of influenza A(H3N2) compared with pH1N1 (reference).

‡OR of influenza B compared with pH1N1 (reference).

observations were reported during the 2011–12 influenza season in the United States (11) and France (8), where influenza A(H3N2) was also the predominant virus and caused excess mortality in the elderly (12–14). Given that the definition of case-patient was established in a season with almost exclusively pH1N1 circulation, the figures for the first postpandemic season with dominant influenza A(H3N2) virus might have been affected by lower definition sensitivity for identifying case-patients infected with other influenza types and subtypes. In addition, according to 2 international cohort studies conducted during 2009–2015 (15), outpatients with influenza A(H3N2) virus infection were less likely to be hospitalized than those infected with pH1N1 or influenza B virus, which might have influenced the numbers reported. Another aspect that could influence the higher number of pH1N1 infections recorded compared with other subtypes is the wider availability of the PCR assay for this virus subtype since the 2009 pandemic in all the laboratories of the hospitals participating in SHCIC surveillance.

Our results are similar to those from previous studies, which found that hospitalized influenza pH1N1-infected patients were younger than those infected with influenza A(H3N2) or B (15). Also, in the United States, a higher proportion of pH1N1 infections occurred in adults 15–64 years of age compared with influenza A(H3N2) and B infections (7). Several observations could be consistent with the differences on age by influenza virus type and subtype found in this study and others. The different susceptibility of each birth cohort is based on the likelihood that their influenza primary infections were with group 1 or 2

hemagglutinin. Individuals born before 1956 likely had their first infection with a group 1 virus and had preexisting cross-reactive antibodies against viruses of the same group as pH1N1 virus, whereas those born in 1968 or later appear protected against severe influenza A(H3N2) infection (16–18). Moreover, seasonal influenza A(H1N1) virus that circulated before 2009 provided some additional cross-reactive immunity protection in older patients against the newer pH1N1 virus (17,18). The younger patients, who have less exposure to this older seasonal influenza A(H1N1) virus, might have experienced more severe disease as a result of direct infection by pH1N1 and the resulting cytokine-induced inflammatory responses, an immune-mediated pathologic process which is believed to play an important role in the onset of severe disease (19–21).

In our study, case-patients infected with influenza A(H3N2) or B viruses were more likely to have underlying medical conditions than those infected with pH1N1. This observation is partly in line with findings from the aforementioned international cohort study (15) and could be consistent with the age difference between influenza virus type and subtype. However, when we stratified the analysis by age, the differences between those pH1N1-infected patients compared with influenza A(H3N2) and B remained significant, regardless of age (Appendix Tables 2–4). In contrast, a study in Argentina reported that the prevalence of underlying medical conditions did not differ between hospitalized patients with influenza A(H3N2) or pH1N1 infection (10).

We found that morbid obesity was more common among case-patients infected with pH1N1. This result

accords with a higher prevalence of obesity (18.2%) found by another study in hospitalized patients with pH1N1 infection compared with patients with influenza A(H3N2) or B infection (<10%) (7). Obesity was first identified as a novel independent risk factor for influenza severity in hospitalized adults during the 2009 pandemic in California (USA) (22). Furthermore, another study found a stronger association between obesity and ICU admission and death for pH1N1 infections (23).

Our results indicate that the likelihood of pneumonia was higher among patients with pH1N1 than patients with influenza A(H3N2) or B infections. However, patients with influenza A(H3N2) or B infections had a higher risk for bacterial or viral coinfection. Although our study lacks information on other clinical features or radiologic findings, the results seem to be in line with previous studies. A US study found that adults with pH1N1 infection had an increased risk for radiographically confirmed pneumonia compared with those with influenza A(H3N2) infection (24). A study in Japan showed that hospitalized patients with pH1N1 virus had primary viral pneumonia more frequently and had mixed bacterial or secondary bacterial pneumonia less frequently compared with patients with influenza A(H3N2) or B virus infections (25). Another study, conducted during the first postpandemic influenza season, showed that patients with pH1N1 pneumonia had similar clinical characteristics but slightly higher disease severity and stronger systemic inflammatory response than patients with influenza A(H3N2) pneumonia (26). In addition, in our study, ARDS occurred more frequently in patients infected with pH1N1 than those infected with influenza A(H3N2) or B viruses, which accords with previous reports from other countries (7,8).

Treatment with antiviral drugs was significantly less common in patients with influenza A(H3N2) or B infections than in patients with pH1N1 infection, regardless of age (Appendix Tables 2–4). We were unable to explain these data because antiviral treatment is recommended for everyone hospitalized with influenza in Spain (27), and the virus type and subtype should not have influenced treatment decisions (28).

Our results indicate that patients with influenza A(H3N2) or B infections were less likely to be admitted to an ICU, die, or both than were those with pH1N1 infections, after controlling for potential confounders. These findings are in agreement with other studies of disease severity by influenza virus type and subtype, which report higher ORs for ICU admission for pH1N1-infected patients (7,9,10,29).

The aforementioned international cohort study showed similar results to our own study for every age group except persons >65 years of age, for which they found higher hospitalization rates for outpatients infected with influenza B (15). In contrast, a study in South Africa showed no association between virus type and subtype and ICU admission or death (4). Other studies did not find differences in patient mortality between influenza A virus subtypes (10), or between other types or subtypes (8,25). In our study, we did not find differences in the risk for ICU admission by influenza A subtype in patients <65 years of age.

We should distinguish at this point the clinical seriousness caused by different influenza virus types and subtypes, as observed in severe influenza surveillance systems, from those results on the effect of influenza on population mortality rates obtained from population-based studies that use regression models. As previously reported, influenza A(H3N2)-dominant epidemics have a considerable impact on mortality, with highest excess mortality attributable to influenza occurring mainly in older adults (12–14,30,31). In addition, a study suggests that influenza B might also be more of a concern in terms of excess mortality in the influenza season 2017–18 (32). However, many of these deaths might have occurred in older persons who have a cascade of illness after an influenza infection, and influenza in older patients might not have a typical clinical profile. Moreover, many older patients might die at home or in managed care facilities and might not get to a hospital. The increase in deaths associated with influenza A(H3N2) at the population level might reflect greater population susceptibility or reduced vaccine effectiveness against influenza A(H3N2) that has become apparent in recent years (33), although it might not reflect the relative clinical seriousness of the individual infection. Therefore, our finding that pH1N1 infections caused a higher clinical seriousness in hospitalized patients than influenza A(H3N2) or B infections is fully congruent with the greater effect on the population mortality caused by influenza A(H3N2) seasons (12–14,30,31).

This study has several limitations. First, we cannot exclude a possible bias that results from using hospitalized case-based surveillance systems with many reporting sites that might have had different testing practices and might also have varied by season. However, because of the high percentage of the national population included in the SHCIC surveillance, the results obtained should be highly representative of the entire country. During the last 4 seasons, a relatively high proportion of influenza A

infections were not subtyped, probably because of the implementation of rapid tests for influenza confirmation. Influenza testing could also have been biased depending on age, severity of symptoms, changes in swabbing practices in the last few seasons, or even as a result of the selection of patients for swabbing based on physician-suspected influenza; however, these factors should not have influenced the virus type and subtype recorded. The multivariable analysis has been controlled for bias by season to avoid potential biases related to the inclusion of several seasons in the study (i.e., differing dominant influenza virus types and subtypes and their antigenic drifts and shifts, influenza vaccine uptake, and seasonal variations in match the vaccine to the circulating influenza strains could all complicate comparisons between seasons). However, a real strength of this study is its representativeness; it enrolled patients from hospitals throughout Spain and across every age group, it covered every influenza season since SHCIC surveillance began in 2009, and it benefited from substantial virus co-circulation and a large sample size.

In conclusion, our findings suggest that hospitalized patients infected with pH1N1 virus had a higher risk for ICU admission, death, or both than patients infected with influenza A(H3N2) or B infections, despite being younger and having fewer underlying medical conditions. Therefore, in those seasons with considerable circulation of pH1N1, more admissions to hospital ICUs should be expected, especially among hospitalized young adult patients. To decrease treatment delays, antiviral treatment should be started shortly after admission to hospital when influenza is suspected. These observations could be of crucial importance when planning resource deployment during influenza epidemics. Understanding the patterns of disease severity associated with influenza and how these patterns might differ among virus types and subtypes can help guide public health measures to control influenza. This knowledge can help in directing resource allocation in the healthcare system during each influenza season and thus can ensure an effective response to pressures on ICUs, especially during pH1N1 epidemics.

### Acknowledgments

We thank members of the Spanish Influenza Surveillance System for their contribution to this work: Virtudes Gallardo, José María Navarro, Miriam García, Ana María Martínez, Ismael Huertas, Santiago Melón, Jaume Giménez, Joana M. Vanrell, Jordi Reina, Carmen Pérez, Luis Viloria, Mónica Gozalo, Sonia Humanes, María Victoria García, Tomás Vega, Socorro Fernández, Gregoria

Megias, Raúl Ortiz de Lejarazu, Iván Sanz, Silvia Rojo, Nuria Torner, María de los Ángeles Marcos, Javier Roig, Julián Mauro Ramos, María Jesús Purriños, Juan García Costa, Sonia Pérez-Castro, Luis García-Comas, Juan Carlos Galán, Ana García-Fulgueira, Antonio Moreno, Jesús Castilla, Mirian Fernández-Alonso, Carmen Ezpeleta, Fernando González-Carril, Gustavo Cilla, Eva Martínez-Ochoa, Carmen Quiñones, Miriam Blasco, Ana Rivas Daniel Castrillejo, Francisco Pozo, and Inmaculada Casas. We are also grateful to Christian Winter for his critical review of the manuscript.

The opinions expressed by authors contributing to this journal article do not necessarily reflect the opinions of the Institute of Health Carlos III or the institutions with which the authors are affiliated.

### About the Author

Dr. Delgado-Sanz is medical epidemiologist at the National Centre of Epidemiology of the Carlos III Health Institute, Madrid, Spain. Her research interests focus on severity, impact, and disease burden of influenza virus.

### References

1. Larrauri Cámara A, Jiménez-Jorge S, Mateo Ontañón S, Pozo Sánchez F, Ledesma Moreno J, Casas Flecha I; Spanish Influenza Surveillance System (SISS). Epidemiology of the 2009 influenza pandemic in Spain. *Enferm Infecc Microbiol Clin*. 2012;30(Suppl 4):2-9. [https://doi.org/10.1016/S0213-005X\(12\)70098-8](https://doi.org/10.1016/S0213-005X(12)70098-8)
2. World Health Organization. Report of the Review Committee on the Functioning of the International Health Regulations (2005) in relation to pandemic (H1N1) 2009 [cited 2018 Oct 10]. <https://apps.who.int/iris/handle/10665/3350>
3. Oliva J, Delgado-Sanz C, Larrauri A; Spanish Influenza Surveillance System. Estimating the burden of seasonal influenza in Spain from surveillance of mild and severe influenza disease, 2010-2016. *Influenza Other Respir Viruses*. 2018;12:161-70. <https://doi.org/10.1111/irv.12499>
4. Cohen AL, Hellferscee O, Pretorius M, Treurnicht F, Walaza S, Madhi S, et al. Epidemiology of influenza virus types and subtypes in South Africa, 2009-2012. *Emerg Infect Dis*. 2014;20:1162-9. <https://doi.org/10.3201/eid2007.131869>
5. Gutiérrez-Pizarra A, Pérez-Romero P, Alvarez R, Aydillo TA, Osorio-Gómez G, Milara-Ibáñez C, et al. Unexpected severity of cases of influenza B infection in patients that required hospitalization during the first post-pandemic wave. *J Infect*. 2012;65:423-30. <https://doi.org/10.1016/j.jinf.2012.07.004>
6. Gubbels S, Krause TG, Bragstad K, Perner A, Mølbak K, Glismann S. Burden and characteristics of influenza A and B in Danish intensive care units during the 2009/10 and 2010/11 influenza seasons. *Epidemiol Infect*. 2013;141:767-75. <https://doi.org/10.1017/S0950268812001471>
7. Chaves SS, Aragon D, Bennett N, Cooper T, D'Mello T, Farley M, et al. Patients hospitalized with laboratory-confirmed influenza during the 2010-2011 influenza season: exploring disease severity by virus type and subtype.



- J Infect Dis. 2013;208:1305–14. <https://doi.org/10.1093/infdis/jit316>
8. Bonmarin I, Belchior E, Bergounioux J, Brun-Buisson C, Mégarbane B, Chappert JL, et al. Intensive care unit surveillance of influenza infection in France: the 2009/10 pandemic and the three subsequent seasons. *Euro Surveill*. 2015;20:30066. <https://doi.org/10.2807/1560-7917.ES.2015.20.46.30066>
  9. Boddington NL, Verlander NQ, Pebody RG. Developing a system to estimate the severity of influenza infection in England: findings from a hospital-based surveillance system between 2010/2011 and 2014/2015. *Epidemiol Infect*. 2017;145:1461–70. <https://doi.org/10.1017/S095026881700005X>
  10. Kuszniarz G, Carolina C, Manuel RJ, Sergio L, Lucila O, Julio B, et al. Impact of influenza in the post-pandemic phase: clinical features in hospitalized patients with influenza A (H1N1) pdm09 and H3N2 viruses, during 2013 in Santa Fe, Argentina. *J Med Virol*. 2017;89:1186–91. <https://doi.org/10.1002/jmv.24758>
  11. Centers for Disease Control and Prevention (CDC). Update: influenza activity – United States, 2011–12 season and composition of the 2012–13 influenza vaccine. *MMWR Morb Mortal Wkly Rep*. 2012;61:414–20.
  12. León-Gómez I, Delgado-Sanz C, Jiménez-Jorge S, Flores V, Simón F, Gómez-Barroso D, et al. Excess mortality associated with influenza in Spain in winter 2012 [in Spanish]. *Gac Sanit*. 2015;29:258–65.
  13. Mazick A, Gergonne B, Nielsen J, Wuillaume F, Virtanen MJ, Fouillet A, et al. Excess mortality among the elderly in 12 European countries, February and March 2012. *Euro Surveill*. 2012;17:20138.
  14. Mølbak K, Espenhain L, Nielsen J, Tersago K, Bossuyt N, Denissov G, et al. Excess mortality among the elderly in European countries, December 2014 to February 2015. *Euro Surveill*. 2015;20:21065. <https://doi.org/10.2807/1560-7917.ES2015.20.11.21065>
  15. Dwyer DE, Lynfield R, Losso MH, Davey RT, Cozzi-Lepri A, Wentworth D, et al.; INSIGHT Influenza Study Group. Comparison of the outcomes of individuals with medically attended influenza A and B virus infections enrolled in 2 international cohort studies over a 6-year period: 2009–2015. *Open Forum Infect Dis*. 2017;4:ofx212. <https://doi.org/10.1093/ofid/ofx212>
  16. Viboud C, Epstein SL. First flu is forever. *Science*. 2016;354:706–7. <https://doi.org/10.1126/science.aak9816>
  17. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. *N Engl J Med*. 2009;361:1945–52. <https://doi.org/10.1056/NEJMoa0906453>
  18. Goh EH, Jiang L, Hsu JP, Tan LWL, Lim WY, Phoon MC, et al. Epidemiology and relative severity of influenza subtypes in Singapore in the post-pandemic period from 2009 to 2010. *Clin Infect Dis*. 2017;65:1905–13. <https://doi.org/10.1093/cid/cix694>
  19. Lee CK, Lee HK, Loh TP, Lai FY, Tambyah PA, Chiu L, et al. Comparison of pandemic (H1N1) 2009 and seasonal influenza viral loads, Singapore. *Emerg Infect Dis*. 2011;17:287–91. <https://doi.org/10.3201/eid1702.100282>
  20. Bermejo-Martin JF, Martin-Loeches I, Rello J, Antón A, Almansa R, Xu L, et al. Host adaptive immunity deficiency in severe pandemic influenza. *Crit Care*. 2010;14:R167. <https://doi.org/10.1186/cc9259>
  21. Paquette SG, Banner D, Zhao Z, Fang Y, Huang SS, León AJ, et al. Interleukin-6 is a potential biomarker for severe pandemic H1N1 influenza A infection. *PLoS One*. 2012;7:e38214. <https://doi.org/10.1371/journal.pone.0038214>
  22. Louie JK, Acosta M, Samuel MC, Schechter R, Vugia DJ, Harriman K, et al.; California Pandemic (H1N1) Working Group. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). *Clin Infect Dis*. 2011;52:301–12. <https://doi.org/10.1093/cid/ciq152>
  23. Fezeu L, Julia C, Henegar A, Bitu J, Hu FB, Grobbee DE, et al. Obesity is associated with higher risk of intensive care unit admission and death in influenza A (H1N1) patients: a systematic review and meta-analysis. *Obes Rev*. 2011;12:653–9. <https://doi.org/10.1111/j.1467-789X.2011.00864.x>
  24. Belongia EA, Irving SA, Waring SC, Coleman LA, Meece JK, Vandermause M, et al. Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008–2009 (H1N1), and 2007–2008 (H3N2) infections. *JAMA*. 2010;304:1091–8. <https://doi.org/10.1001/jama.2010.1277>
  25. Ishiguro T, Takayanagi N, Kanauchi T, Uozumi R, Kawate E, Takaku Y, et al. Clinical and radiographic comparison of influenza virus-associated pneumonia among three viral subtypes. *Intern Med*. 2016;55:731–7. <https://doi.org/10.2169/internalmedicine.55.5227>
  26. Yang SQ, Qu JX, Wang C, Yu XM, Liu YM, Cao B. Influenza pneumonia among adolescents and adults: a concurrent comparison between influenza A (H1N1) pdm09 and A (H3N2) in the post-pandemic period. *Clin Respir J*. 2014;8:185–91. <https://doi.org/10.1111/crj.12056>
  27. Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Red Nacional de Vigilancia Epidemiológica. Protocolo de vigilancia de la Gripe. In: *Protocolos de la Red Nacional de Vigilancia Epidemiológica*. Madrid, 2013 [cited 2019 Jul 26]. [https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/PROTOCOLOS/PROTOCOLOS%20EN%20BLOQUE/PROTOCOLOS\\_RENAVE-ciber.pdf](https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/PROTOCOLOS/PROTOCOLOS%20EN%20BLOQUE/PROTOCOLOS_RENAVE-ciber.pdf)
  28. World Health Organization. Guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses. Part I: recommendations [cited 2018 Oct 10]. [http://www.who.int/csr/resources/publications/swineflu/h1n1\\_guidelines\\_pharmaceutical\\_mngt.pdf?ua=1](http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf?ua=1)
  29. Dimitrijević D, Ilić D, Rakić Adrović S, Šuljagić V, Pelešić M, Stevanović G, et al. Predictors of hospitalization and admission to intensive care units of influenza patients in Serbia through four influenza seasons from 2010/2011 to 2013/2014. *Jpn J Infect Dis*. 2017;70:275–83. <https://doi.org/10.7883/yoken.JJID.2016.210>
  30. Kwok KO, Riley S, Perera RAPM, Wei VWI, Wu P, Wei L, et al. Relative incidence and individual-level severity of seasonal influenza A H3N2 compared with 2009 pandemic H1N1. *BMC Infect Dis*. 2017;17:337. <https://doi.org/10.1186/s12879-017-2432-7>
  31. Lytras T, Pantavou K, Mouratidou E, Tsiodras S. Mortality attributable to seasonal influenza in Greece, 2013 to 2017: variation by type and subtype and age, and a possible harvesting effect. *Euro Surveill*. 2019;24:1800118. <https://doi.org/10.2807/1560-7917.ES.2019.24.14.1800118>
  32. Nielsen J, Vestergaard LS, Richter L, Schmid D, Bustos N, Asikainen T, et al. European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered? *Clin Microbiol Infect*. 2019;25:1266–76. <https://doi.org/10.1016/j.cmi.2019.02.011>
  33. Belongia EA, McLean HQ. Influenza vaccine effectiveness: defining the H3N2 problem. *Clin Infect Dis*. 2019;69:1817–23. <https://doi.org/10.1093/cid/ciz411>

Address for correspondence: Concepción Delgado-Sanz, Institute of Health Carlos III, National Centre of Epidemiology, Monforte de Lemos 5, 28029 Madrid, Spain; email: cdelgados@isciii.es

# Illness Severity in Hospitalized Influenza Patients by Virus Type and Subtype, Spain, 2010–2017

## Appendix

### Severe Hospitalized confirmed Influenza Cases-Patients Surveillance System

The Severe Hospitalized confirmed Influenza cases-patients (SHCIC) Surveillance System was initiated during the 2009 influenza pandemic and has been consolidated throughout the post-pandemic seasons (2010–11/2017–18). In this surveillance system a network of hospitals and public health units at regional level located throughout Spain are participating. The Surveillance System, which operates within the Spanish Influenza Surveillance System, is coordinated by National Center of Epidemiology (CNE), Carlos III Health Institute (ISCIII).

### Main Surveillance Objectives

- To describe the epidemiologic and virological characteristics of severe influenza disease
- To identify risk factors for severe influenza disease by age group
- To describe the burden of severe influenza disease by age and risk groups
- To compare the pattern of severity among influenza epidemics or pandemics
- To provide information to public health policy makers to guide the influenza prevention and control measures

### Case-Patient Definition

Any person who present a clinical picture compatible with influenza and who require hospital admission will be swabbed. From those, a severe hospitalized confirmed influenza case-patient is any person who is hospitalize with at least one of the following clinical criteria:

pneumonia, acute respiratory distress syndrome (ARDS), multiple organ dysfunction syndrome (MODS), septic shock or admission to intensive care unit (ICU), AND is laboratory confirmed influenza. Laboratory confirmation is defined as a positive result from viral culture, reverse transcription-PCR (RT-PCR), identification of influenza virus antigen or antibody testing.

## **Population under Surveillance and Geographic Coverage**

In the surveillance of SHCIC, hospitals designated for that purpose by each of the 19 Autonomous Regions are involved, ranging from 181, in the 2010–2011 season, to 90 in the 2013–2014 season. The population under surveillance correspond to the reference catchment population of these hospitals ranging from 59% in the 2010–2011 season to 40% in the 2012–2013 season. In the 2017–18 season, the population included in the surveillance of SHCIC was 23,460,172 inhabitants, which represents 51% of the Spanish population.

## **Type of Surveillance**

SHCIC surveillance system is a hospital-based surveillance considered passive, voluntary and prospective.

## **Specification of Data Collection**

- Case-based dataset format
- Key variables:
  - Demographic: age, sex, region
  - Dates of hospital admission, symptom onset, influenza vaccination, antiviral treatment and hospital discharge
  - Virus type and subtype
  - Genetically characterized influenza virus
  - Clinical: Underlying medical conditions and complications
  - Antiviral treatment and influenza vaccination status

- Outcome: ICU admission, death
- Frequency of data collection: weekly
- Responsible for data collection: Health professionals from Preventive Medicine Departments at the hospitals involved in SHCIC surveillance system, and Public Health professionals at regional level responsible for such surveillance.

## **Flowchart of Spanish Severe Hospitalized Confirmed Influenza Case-Patients Surveillance System**

Appendix Figure shows the steps included in the case collection, data flow, data analysis and dissemination of results, which are within the SHCIC surveillance system

### **Reporting Format**

The data are collected on different electronic format at regional level, and subsequently they are transformed in a standard txt file

### **Data Entry**

Weekly, each regional surveillance network is responsible for entering the data through a Web application of the Spanish Influenza Surveillance System (<http://vgripe.isciii.es>). Data are weekly retrieved at the National Center of Epidemiology, which is responsible for their analysis and the elaboration and release of the National Weekly Influenza Report.

### **Statistical Models**

Univariate multinomial logistic regression models were performed to compare demographic and clinical characteristics across influenza virus types and subtypes. Including as dependent variable the influenza virus type and subtype, considering as reference category A(H1N1)pdm09 (pH1N1); and as independent variables each of the characteristics of interest: age groups (0–14, 15–64, <64 years), sex, presence of underlying medical conditions (chronic respiratory, cardiovascular, renal or liver diseases, class III obesity, diabetes mellitus, or

immunosuppression), antiviral treatment and seasonal influenza vaccination status. The effect of each predictor in the model is measured as relative risk ratio (RRR).

The regression equation used in univariate analyses for each variable of interest:

$$\text{Log (P(virus = AH3N2)/P(virus = pH1N1))} = b_{10} + b_{11} * \text{variable} + \epsilon$$

$$\text{Log (P(virus = B)/P(virus = pH1N1))} = b_{20} + b_{21} * \text{variable} + \epsilon$$

In addition, we performed the same analysis stratified by age groups (0–14, 15–64, <64 years) to investigate what the effect of age is on some of the associations found. The results of these analyzes are shown in Appendix Tables 2–4.

To estimate the odds ratios (OR) for developing clinical complications or death, we also conducted univariate logistic regression models, considering as dependent variables in each of the models, each of possible complications: pneumonia, any laboratory-confirmed viral or bacterial co-infection, acute respiratory distress syndrome (ARDS), multiple organ dysfunction syndrome (MODS) or admission to an intensive care unit (ICU); and death. Explanatory variable studied was the influenza virus type and subtype, taking as reference category pH1N1 virus. We compared patients infected with A(H3N2) or B against patients with pH1N1.

The regression equations used:

$$\text{Log (odds of pneumonia)} = \alpha + \beta_1 * \text{virus} + \epsilon$$

$$\text{Log (odds of co-infection)} = \alpha + \beta_1 * \text{virus} + \epsilon$$

$$\text{Log (odds of ARDS)} = \alpha + \beta_1 * \text{virus} + \epsilon$$

$$\text{Log (odds of MODS)} = \alpha + \beta_1 * \text{virus} + \epsilon$$

$$\text{Log (odds of ICU)} = \alpha + \beta_1 * \text{virus} + \epsilon$$

$$\text{Log (odds of death)} = \alpha + \beta_1 * \text{virus} + \epsilon$$

Multivariate logistic regressions models were performed to explore the effect of influenza virus type and subtype as an independent factor for the following severe outcomes: 1) admission to ICU, 2) death and 3) either admission to ICU or death, or both, using pH1N1 as the reference category. All these models were adjusted for potential confounding: sex, age, influenza season, underlying medical conditions (comorbidity), pneumonia, antiviral treatment and seasonal

trivalent influenza vaccine. We also performed the same analysis stratified by age groups (0–14, 15–64, <64 years). The results of these analyses are shown in Appendix Table 1.

The regression equations used in adjusted analyses are:

$$\text{Log (odds of ICU)} = \alpha + \beta_1 * \text{virus} + \beta_2 * \text{sex} + \beta_3 * \text{age} + \beta_4 * \text{season} + \beta_5 * \text{comorbidity} + \beta_6 * \text{pneumonia} + \beta_7 * \text{antiviral} + \beta_8 * \text{vaccine} + \epsilon$$

$$\text{Log (odds of death)} = \alpha + \beta_1 * \text{virus} + \beta_2 * \text{sex} + \beta_3 * \text{age} + \beta_4 * \text{season} + \beta_5 * \text{comorbidity} + \beta_6 * \text{pneumonia} + \beta_7 * \text{antiviral} + \beta_8 * \text{vaccine} + \epsilon$$

$$\text{Log (odds of ICU or death)} = \alpha + \beta_1 * \text{virus} + \beta_2 * \text{sex} + \beta_3 * \text{age} + \beta_4 * \text{season} + \beta_5 * \text{comorbidity} + \beta_6 * \text{pneumonia} + \beta_7 * \text{antiviral} + \beta_8 * \text{vaccine} + \epsilon$$

**Appendix Table 1.** Effect of Influenza virus type or subtype on the severity outcome of laboratory-confirmed patients hospitalized for severe influenza, by age group, Spain, influenza seasons 2010–11 to 2016–17\*

Age group and influenza virus type or subtype	ICU†			Death‡			ICU/ death§		
	No. (%)	Crude OR (95% CI)	Adjusted OR (95% CI)	No. (%)	Crude OR (95% CI)	Adjusted OR (95% CI)	No. (%)	Crude OR (95% CI)	Adjusted OR (95% CI)
0–14 y									
pH1N1	144 (27)	Ref	Ref	10 (2)	Ref	Ref	145 (28)	Ref	Ref
A(H3N2)	95 (29)	1.10 (0.81–1.50)	0.64 (0.31–1.12)	3 (1)	0.50 (0.14–1.83)	0.15 (0.01–2.77)	96 (30)	1.10 (0.81–1.50)	0.63 (0.30–1.30)
B	80 (26)	0.94 (0.69–1.30)	0.69 (0.41–1.15)	4 (1)	0.74 (0.23–2.38)	0.12 (0.01–1.29)	81 (28)	1.01 (0.73–1.39)	0.70 (0.42–1.17)
15–64 y									
pH1N1	1,239 (47)	Ref	Ref	318 (12)	Ref	Ref	1,304 (51)	Ref	Ref
A(H3N2)	290 (43)	0.83 (0.70–0.99)	0.68 (0.46–0.99)	76 (11)	0.88 (0.67–1.15)	0.51 (0.27–0.97)	316 (47)	0.86 (0.72–1.02)	0.61 (0.41–0.90)
B	160 (39)	0.71 (0.58–0.88)	0.59 (0.42–0.84)	29 (7)	0.57 (0.38–0.84)	0.32 (0.16–0.63)	169 (44)	0.75 (0.60–0.93)	0.55 (0.38–0.77)
>64 y									
pH1N1	402 (34)	Ref	Ref	256 (22)	Ref	Ref	516 (45)	Ref	Ref
A(H3N2)	434 (22)	0.56 (0.47–0.65)	0.79 (0.55–1.14)	410 (21)	0.94 (0.79–1.12)	0.59 (0.39–0.87)	717 (38)	0.75 (0.65–0.87)	0.70 (0.51–0.97)
B	149 (28)	0.76 (0.61–0.95)	0.56 (0.38–0.84)	96 (18)	0.80 (0.62–1.04)	0.46 (0.29–0.73)	200 (39)	0.81 (0.65–0.99)	0.53 (0.37–0.75)
All ages									
pH1N1	1,787 (41)	Ref	Ref	585 (14)	Ref	Ref	1,967 (46)	Ref	Ref
A(H3N2)	820 (28)	0.55 (0.50–0.61)	0.56 (0.44–0.71)	493 (16)	1.25 (1.10–1.43)	0.56 (0.40–0.77)	1,133 (39)	0.74 (0.67–0.81)	0.59 (0.47–0.73)
B	389 (31)	0.64 (0.56–0.73)	0.51 (0.41–0.63)	130 (11)	0.76 (0.6–0.93)	0.38 (0.26–0.54)	451 (38)	0.71 (0.62–0.81)	0.50 (0.40–0.62)

\*Multivariate analysis adjusted for sex, age, season influenza, underlying medical conditions, pneumonia, antiviral treatment, and seasonal trivalent influenza vaccine. ICU, intensive care unit; OR, odds ratio.

†ICU case-patients compared with non-ICU case-patients.

‡Death case-patients compared with non-death case-patients.

§Either ICU admission or death, or both case-patients compared with non-ICU and non-death case-patients.

**Appendix Table 2.** Demographic and clinical characteristics of severe hospitalized confirmed influenza case-patients <15 y old, by type and subtype of influenza virus and age group in Spain, seasons 2010–11 to 2016–17\*

Characteristic	Type and subtype of influenza virus				
	pH1N1	A(H3N2)	Crude RRR† (95% CI)	B	Crude RRR‡ (95% CI)
	n = 566	n = 333		n = 318	
No. (%)	No. (%)	No. (%)	No. (%)		
Sex (males)	320 (56)	201 (60)	1.17 (0.89–1.54)	164 (52)	0.82 (0.62–1.08)
Underlying medical condition§	107 (26)	88 (39)	1.86 (1.32–2.63)	98 (40)	1.96 (1.40–2.74)
Class III obesity (BMI ≥40 kg/m <sup>2</sup> )	3 (0.6)	1 (0.3)	0.56 (0.06–5.42)	1 (0.4)	0.62 (0.06–6.02)
Chronic respiratory diseases	37 (9)	26 (9)	1.07 (0.63–1.81)	25 (10)	1.20 (0.70–2.04)
Chronic cardiovascular diseases	22 (4)	13 (4)	0.99 (0.49–1.99)	27 (10)	2.42 (1.35–4.34)
Diabetes mellitus	7 (1)	6 (2)	1.45 (0.48–4.37)	11 (4)	2.99 (1.15–7.83)
Renal diseases	6 (1)	1 (0.3)	0.28 (0.03–2.38)	6 (2)	1.93 (0.22–6.05)
Chronic liver disease	2 (0.4)	1 (0.3)	0.84 (0.76–9.31)	1 (0.4)	0.94 (0.08–10.38)
Immunosuppression	18 (4)	13 (4)	1.23 (0.60–2.55)	13 (5)	1.37 (0.66–2.83)
Antiviral treatment	293 (56)	124 (39)	0.51 (0.38–0.68)	118 (41)	0.56 (0.42–0.75)
Seasonal trivalent influenza vaccine	16 (3)	24 (8)	2.62 (1.37–5.01)	19 (8)	2.46 (1.24–4.87)

\*RRR, relative risk ratio; CI, confidence interval; BMI, body mass index.

†A(H3) vs. pH1N1 (reference). ‡B vs. pH1N1 (reference).

§Underlying medical conditions: one or more of class III obesity, (BMI ≥40 kg/m<sup>2</sup>), chronic respiratory diseases, chronic cardiovascular diseases, diabetes mellitus, renal diseases, chronic liver disease, or immunosuppression.

**Appendix Table 3.** Demographic and clinical characteristics of severe hospitalized confirmed influenza cases-patients between 15–64 y old, by type and subtype of influenza virus and age group in Spain, seasons 2010–11 to 2016–17\*

Characteristic	Type and subtype of influenza virus				
	pH1N1	A(H3N2)	Crude RRR† (95% CI)	B	Crude RRR‡ (95% CI)
	n = 2,767	n = 716		n = 437	
No. (%)	No. (%)	No. (%)	No. (%)		
Sex (males)	1,542 (56)	378 (53)	0.89 (0.75–1.05)	250 (57)	1.07 (0.87–1.31)
Underlying medical condition§	1,386 (67)	439 (84)	2.50 (1.94–3.21)	239 (74)	1.39 (1.07–1.81)
Class III obesity (BMI ≥40 kg/m <sup>2</sup> )	330 (15)	63 (11)	0.72 (0.54–0.96)	38 (11)	0.71 (0.50–1.01)
Chronic respiratory diseases	366 (19)	151 (30)	1.74 (1.39–2.17)	73 (24)	1.31 (0.99–1.75)
Chronic cardiovascular diseases	335 (14)	107 (18)	1.29 (1.01–1.62)	55 (15)	0.97 (0.71–1.31)
Diabetes mellitus	375 (16)	130 (21)	1.42 (1.14–1.78)	56 (16)	1.15 (0.97–1.36)
Renal diseases	141 (6)	51 (8)	1.44 (1.03–2.01)	30 (8)	1.41 (0.93–2.12)
Chronic liver disease	168 (7)	72 (12)	1.74 (1.30–2.31)	33 (9)	1.31 (0.88–1.93)
Immunosuppression	414 (18)	133 (22)	1.31 (1.05–1.63)	85 (24)	1.44 (1.10–1.88)
Antiviral treatment	2,457 (91)	586 (84)	0.48 (0.38–0.62)	310 (74)	0.27 (0.21–0.35)
Seasonal trivalent influenza vaccine	220 (10)	116 (19)	2.20 (1.72–2.81)	57 (19)	1.85 (1.35–2.54)

\*RRR, relative risk ratio; CI, confidence interval; BMI, body mass index.

†A(H3) vs. pH1N1 (reference).

‡B vs. pH1N1 (reference).

§Underlying medical conditions: one or more of class III obesity, (BMI ≥40 kg/m<sup>2</sup>), chronic respiratory diseases, chronic cardiovascular diseases, diabetes mellitus, renal diseases, chronic liver disease, or immunosuppression.

**Appendix Table 4.** Demographic and clinical characteristics of severe hospitalized confirmed influenza cases-patients between >64 y of age, by type and subtype of influenza virus and age group in Spain, seasons 2010–11 to 2016–17\*

Characteristic	Type and subtype of influenza virus				
	pH1N1	A(H3N2)	Crude RRR† (95% CI)	B	Crude RRR‡ (95% CI)
	n = 1,231	n = 2,035		n = 567	
No. (%)	No. (%)	No. (%)	No. (%)		
Sex (males)	725 (59)	1,057 (52)	0.76 (0.65–0.87)	321 (57)	0.91 (0.75–1.12)
Underlying medical condition§	838 (90)	1,523 (93)	1.48 (1.11–1.97)	413 (92)	1.35 (0.89–2.03)
Class III obesity (BMI ≥40 kg/m <sup>2</sup> )	113 (12)	140 (9)	0.70 (0.54–0.90)	41 (9)	0.72 (0.50–1.05)
Chronic respiratory diseases	283 (35)	502 (34)	0.97 (0.81–1.16)	140 (36)	1.03 (0.80–1.33)
Chronic cardiovascular diseases	443 (45)	928 (54)	1.40 (1.20–1.64)	222 (47)	1.08 (0.86–1.34)
Diabetes mellitus	313 (32)	617 (36)	1.20 (1.02–1.42)	157 (34)	1.15 (0.97–1.36)
Renal diseases	188 (19)	341 (20)	1.06 (0.87–1.29)	94 (20)	1.05 (0.80–1.39)
Chronic liver disease	42 (4)	74 (4)	1.01 (0.69–1.49)	24 (5)	1.20 (0.72–2.00)
Immunosuppression	200 (21)	180 (11)	0.46 (0.373–0.57)	72 (16)	0.70 (0.52–0.95)
Antiviral treatment	1,033 (87)	1,526 (77)	0.50 (0.41–0.61)	370 (69)	0.34 (0.26–0.43)
Seasonal trivalent influenza vaccine	447 (42)	1,086 (59)	1.99 (1.71–2.33)	249 (55)	1.64 (1.32–2.05)

\*RRR, relative risk ratio; CI, confidence interval; BMI, body mass index.


†A(H3) vs. pH1N1 (reference).

‡B vs. pH1N1 (reference).

§Underlying medical conditions: one or more of class III obesity, (BMI ≥40 kg/m<sup>2</sup>), chronic respiratory diseases, chronic cardiovascular diseases, diabetes mellitus, renal diseases, chronic liver disease, or immunosuppression.

¶Pregnancy among women of childbearing age (15–49 y of age).





**Appendix Figure.** Flowchart of Spanish Severe Hospitalized confirmed Influenza cases-patients surveillance system.